Chengdu Peide Biopharmaceutical
AI-powered peptide drug screening and development platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Seed | |
| Total Funding | 000k | ||
Chengdu Peide Biopharmaceutical Co., Ltd. is a biopharmaceutical company established in 2021 and based in Chengdu, Sichuan, China. The company focuses on developing new peptide drugs, particularly those derived from animal toxins, to address the side effects associated with traditional chemical drugs. It utilizes a combination of artificial intelligence (AI), multi-omics, and high-throughput screening technologies to accelerate the discovery and development process.
The company's core technological strength lies in its extensive animal toxin peptide library, which it claims is the largest of its kind globally. By integrating biological technology (BT) and information technology (IT), Chengdu Peide has created a massive natural peptide database. This allows for virtual screening and computer-aided drug design to identify and optimize promising peptide candidates before they undergo physical lab testing, significantly shortening development timelines and reducing costs. The company's business model involves leveraging this platform for internal drug development and potentially forming technology collaborations and patent conversions. Its drug pipeline includes candidates for conditions such as pulmonary fibrosis, which have shown promising results in animal trials.
Founded by a team led by scientists from the Chinese Academy of Sciences, the company has successfully raised capital to advance its research. It secured an angel round of several tens of millions of CNY in April 2022 from Tianfu International Bio-city Investment. This was followed by a Seed round in December 2023, which raised CNY 20 million from investors including Sichuan Development Academician Fund and Huaxi Securities.
Keywords: peptide drug development, AI drug discovery, biopharmaceutical, animal toxins, multi-omics, high-throughput screening, peptide library, drug screening platform, preclinical research, pulmonary fibrosis, Chinese Academy of Sciences, biotechnology, Chengdu, Sichuan, PD-DP-008, PD-016, PD-005, synthetic peptide